Although the CheckMate-9ER trial, comparing cabozantinib plus nivolumab to sunitinib in frontline metastatic renal cell carcinoma (mRCC), had recently demonstrated superiority in progression-free survival (PFS) and overall...
Read More
Test your knowledge on results on PsA released at ACR Convergence 2020 – take our quiz and...
Read MoreIn the phase 3 multicenter, open-label, randomized CLEAR trial, lenvatinib in combination with pembrolizumab or everolimus demonstrated significant benefits over sunitinib in patients with advanced renal cell carcinoma (RCC)....
Read More1) In an updated analysis of the phase 2 DESTINY-Breast01 study, women with HER2-positive metastatic breast cancer ADC trastuzumab deruxtecan (Enhertu) continued to demonstrate favorable data, including a median progression-free...
Read More
Test your knowledge on SABCS 2020 – take our quiz and see how you compare with your...
Read MoreWhich of the following is a preliminary outcome of the retrospective, multi-center observational study in a cohort of Italian MS patients investigating the impact of disease-modifying treatments on COVID-19 course of disease?a)...
Read MorePembrolizumab plus axitinib is superior to sunitinib for the treatment of patients with treatment-naïve, advanced renal cell carcinoma (RCC), according to the most recent exploratory analysis of data from the KEYNOTE-426 study....
Read More
It’s no question that advancements in the treatment of dry eye were impressive at AAO 2020....
Read More
It’s no question that advancements in the treatment of age-related macular degeneration were...
Read More
People with multiple sclerosis (MS) may expect worsening symptoms with rising average...
Read More
A retrospective analysis found that in patients with muscle-invasive bladder cancer (MIBC)...
Read MoreRadionuclide therapy directed towards prostate-specific membrane antigen (PSMA) demonstrated promising results in men with docetaxel-treated metastatic castration-resistant prostate cancer (mCRPC) [1]. A phase 2 trial compared...
Read More
Tyrosine kinase inhibitor axitinib elicited a 31% response rate in a phase 2 clinical trial that...
Read More
A phase 2 trial demonstrated encouraging outcomes from retroperitoneal lymph node dissection...
Read More
A team of researchers reported that socioeconomic, racial/ethnic, and gender factors influence the...
Read More
MRI is non-inferior to CT for the surveillance of stage 1 testicular seminoma. Over a 6-year...
Read More
Of nearly 80,000,000 USD in funding for bladder cancer research between 2017 and 2019,...
Read More
In CheckMate 9ER, patients with renal cell cancer (RCC) treated with nivolumab plus cabozantinib...
Read More
Determination of human papillomavirus (HPV) status should be done routinely at diagnosis of penile...
Read More
Cure rates for patients with poor- and intermediate-risk metastatic germ cell tumors lag behind...
Read More
